Effect of the Thiotepa dose in the TBF Conditioning regimen in Patients Undergoing Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia in complete remission: A report from the EBMT Acute Leukemia Working Party

This study suggested that a lower dose-intensity of thiotepa and busulfan (5 mg/kg thiotepa and 2 days of iv busulfan at 6.4 mg/kg (T1B2F) in the TBF regimen may yield better outcomes.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 26, 2020 Category: Hematology Authors: Jean El-Cheikh, Myriam Labopin, Farouk Al-Chami, Ali Bazarbachi, Emanuele Angelucci, Stella Santarone, Francesca Bonifazi, Angelo Michele Carella, Luca Castagna, Benedetto Bruno, Anna Paola Iori, Giorgio La Nasa, Bipin Savani, Arnon Nagler, Mohamad Mohty Tags: Original Study Source Type: research